跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
锐可博 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Imipenem, Cilastatin Sodium and Relebactam for Injection
Approved
化学药品
Imipenem, Cilastatin Sodium and Relebactam for Injection
Merck Sharp & Dohme BV
🇨🇳 National Medical Products Administration
Approval Date
Dec 11, 2024
Approval ID
8f0QjXS9iN1
Company
Merck Sharp & Dohme BV
Type
化学药品
Approval Details
Approval Id
8f0QjXS9iN1
Approval Number
国药准字HJ20240140
Generic Name
注射用亚胺西瑞
Generic Name En
Imipenem, Cilastatin Sodium and Relebactam for Injection
Trade Name
锐可博
Drug Type
化学药品
Dosage Form
注射剂
Strength
1.25g（C₁₂H₁₇N₃O₄S 0.5g，C₁₆H₂₆N₂O₅S 0.5g与C₁₂H₂₀N₄O₆S 0.25g）
Reg Date
2024-12-11
Expired Date
2029-11-30
Company Name
Merck Sharp & Dohme BV
Production Company Name
Merck, Inc.
Company Detail Path
/organization/merck-sharp-and-dohme-bv
Production Company Detail Path
/organization/merck-inc
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Dec 11, 2024
Approval ID
8f0QjXS9iN1
Type
化学药品
Back to NMPA Approvals
